


a 2012 0130

The present invention relates to the delta crystalline form of perindopril L-arginine salt of formula (I):



characterized by the following X-ray powder diffraction peaks measured using a diffractometer with a copper anticathode and expressed in terms of Bragg's angle  $2\theta$  ( $^{\circ}$ ): 4.3, 11.0, 11.1, 13.2, 14.6, 16.0 and 21.9;

and to a process for its preparation by crystallization or recrystallisation from a binary mixture of acetonitrile, ethyl acetate or methyl tert-butyl ether and dimethyl sulphoxide or a ternary mixture of acetonitrile, dimethyl sulphoxide and toluene, at a temperature higher than  $20^{\circ}$ ;

and to pharmaceutical compositions containing it.

The process described provides the obtaining of delta crystalline form of perindopril L-arginine salt of formula (I), possessing a high stability.

Claims: 16